Skip to main content
Top
Published in:

16-01-2024 | Respiratory Microbiota | Review Article

Edible traditional Chinese medicines improve type 2 diabetes by modulating gut microbiotal metabolites

Authors: Shen Chen, Yiqiao Jiao, Yiyang Han, Jie Zhang, Yuanyuan Deng, Zilu Yu, Jiao Wang, Shasha He, Wei Cai, Jixiong Xu

Published in: Acta Diabetologica | Issue 4/2024

Login to get access

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic disorder with intricate pathogenic mechanisms. Despite the availability of various oral medications for controlling the condition, reports of poor glycemic control in type 2 diabetes persist, possibly involving unknown pathogenic mechanisms. In recent years, the gut microbiota have emerged as a highly promising target for T2DM treatment, with the metabolites produced by gut microbiota serving as crucial intermediaries connecting gut microbiota and strongly related to T2DM. Increasingly, traditional Chinese medicine is being considered to target the gut microbiota for T2DM treatment, and many of them are edible. In studies conducted on animal models, edible traditional Chinese medicine have been shown to primarily alter three significant gut microbiotal metabolites: short-chain fatty acids, bile acids, and branched-chain amino acids. These metabolites play crucial roles in alleviating T2DM by improving glucose metabolism and reducing inflammation. This review primarily summarizes twelve edible traditional Chinese medicines that improve T2DM by modulating the aforementioned three gut microbiotal metabolites, along with potential underlying molecular mechanisms, and also incorporation of edible traditional Chinese medicines into the diets of T2DM patients and combined use with probiotics for treating T2DM are discussed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Magliano DJ, Boyko EJ, committee IDFDAtes. IDF Diabetes Atlas. Idf diabetes atlas. Brussels: International Diabetes Federation© International Diabetes Federation, 2021 (2021). Magliano DJ, Boyko EJ, committee IDFDAtes. IDF Diabetes Atlas. Idf diabetes atlas. Brussels: International Diabetes Federation© International Diabetes Federation, 2021 (2021).
2.
go back to reference Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ (2022) Type 2 diabetes. Lancet 400(10365):1803–1820PubMedCrossRef Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ (2022) Type 2 diabetes. Lancet 400(10365):1803–1820PubMedCrossRef
3.
go back to reference Boutari C, DeMarsilis A, Mantzoros CS (2023) Obesity and diabetes. Diabetes Res Clin Pract 202:110773PubMedCrossRef Boutari C, DeMarsilis A, Mantzoros CS (2023) Obesity and diabetes. Diabetes Res Clin Pract 202:110773PubMedCrossRef
4.
go back to reference Li H, Wang L, Huang J, Li B, Qiu T (2022) The relationship between the knowledge of diabetes mellitus and the mental, psychological and emotional status of T2DM patients based on a structural equation model. Sci Rep 12(1):20714PubMedPubMedCentralCrossRef Li H, Wang L, Huang J, Li B, Qiu T (2022) The relationship between the knowledge of diabetes mellitus and the mental, psychological and emotional status of T2DM patients based on a structural equation model. Sci Rep 12(1):20714PubMedPubMedCentralCrossRef
5.
go back to reference Aschner P, Gagliardino JJ, Ilkova H, Lavalle F, Ramachandran A, Mbanya JC et al (2020) Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia 63(4):711–721PubMedPubMedCentralCrossRef Aschner P, Gagliardino JJ, Ilkova H, Lavalle F, Ramachandran A, Mbanya JC et al (2020) Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia 63(4):711–721PubMedPubMedCentralCrossRef
6.
go back to reference Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ (2013) Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36(11):3411–3417PubMedPubMedCentralCrossRef Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ (2013) Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36(11):3411–3417PubMedPubMedCentralCrossRef
7.
go back to reference Athanasopoulou K, Adamopoulos PG, Scorilas A (2003) Unveiling the human gastrointestinal tract microbiome: the past, present, and future of metagenomics. Biomedicines 511(3). Athanasopoulou K, Adamopoulos PG, Scorilas A (2003) Unveiling the human gastrointestinal tract microbiome: the past, present, and future of metagenomics. Biomedicines 511(3).
9.
go back to reference Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T et al (2016) Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352(6285):565–569PubMedPubMedCentralCrossRef Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T et al (2016) Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352(6285):565–569PubMedPubMedCentralCrossRef
10.
go back to reference Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U et al (2019) Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet 51(4):600–605PubMedPubMedCentralCrossRef Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U et al (2019) Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet 51(4):600–605PubMedPubMedCentralCrossRef
11.
go back to reference Reitmeier S, Kiessling S, Clavel T, List M, Almeida EL, Ghosh TS et al (2020) Arrhythmic gut microbiome signatures predict risk of Type 2 diabetes. Cell Host Microbe 28(2):258–72.e6PubMedCrossRef Reitmeier S, Kiessling S, Clavel T, List M, Almeida EL, Ghosh TS et al (2020) Arrhythmic gut microbiome signatures predict risk of Type 2 diabetes. Cell Host Microbe 28(2):258–72.e6PubMedCrossRef
12.
go back to reference Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, et al. (2020) Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care 8(1). Perraudeau F, McMurdie P, Bullard J, Cheng A, Cutcliffe C, Deo A, et al. (2020) Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. BMJ Open Diabetes Res Care 8(1).
13.
go back to reference Liu L, Zhang J, Cheng Y, Zhu M, Xiao Z, Ruan G et al (2022) Gut microbiota: a new target for T2DM prevention and treatment. Front Endocrinol (Lausanne) 13:958218PubMedCrossRef Liu L, Zhang J, Cheng Y, Zhu M, Xiao Z, Ruan G et al (2022) Gut microbiota: a new target for T2DM prevention and treatment. Front Endocrinol (Lausanne) 13:958218PubMedCrossRef
14.
go back to reference Croci S, D'Apolito LI, Gasperi V, Catani MV, Savini I (2021) Dietary Strategies for Management of Metabolic Syndrome: Role of Gut microbiota metabolites. Nutrients 13(5). Croci S, D'Apolito LI, Gasperi V, Catani MV, Savini I (2021) Dietary Strategies for Management of Metabolic Syndrome: Role of Gut microbiota metabolites. Nutrients 13(5).
15.
go back to reference Vallianou NG, Stratigou T, Tsagarakis S (2019) Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones (Athens) 18(2):141–144PubMedCrossRef Vallianou NG, Stratigou T, Tsagarakis S (2019) Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones (Athens) 18(2):141–144PubMedCrossRef
16.
go back to reference Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L et al (2018) Structural Alteration of gut microbiota during the amelioration of human Type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial. mBio 9(3). Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L et al (2018) Structural Alteration of gut microbiota during the amelioration of human Type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula: a multicenter, randomized, open label clinical trial. mBio 9(3).
17.
go back to reference Ye J, Wu Z, Zhao Y, Zhang S, Liu W, Su Y (2022) Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: advanced research-based review. Front Microbiol 13:1029890PubMedPubMedCentralCrossRef Ye J, Wu Z, Zhao Y, Zhang S, Liu W, Su Y (2022) Role of gut microbiota in the pathogenesis and treatment of diabetes mullites: advanced research-based review. Front Microbiol 13:1029890PubMedPubMedCentralCrossRef
18.
go back to reference Magkos F, Hjorth MF, Astrup A (2020) Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16(10):545–555PubMedCrossRef Magkos F, Hjorth MF, Astrup A (2020) Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16(10):545–555PubMedCrossRef
19.
go back to reference Xue H, Wang W, Bian J, Gao Y, Hao Z, Tan J (2022) Recent advances in medicinal and edible homologous polysaccharides: extraction, purification, structure, modification, and biological activities. Int J Biol Macromol 222(Pt A):1110–1126PubMedCrossRef Xue H, Wang W, Bian J, Gao Y, Hao Z, Tan J (2022) Recent advances in medicinal and edible homologous polysaccharides: extraction, purification, structure, modification, and biological activities. Int J Biol Macromol 222(Pt A):1110–1126PubMedCrossRef
20.
go back to reference Li X, He Y, Zeng P, Liu Y, Zhang M, Hao C et al (2019) Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China. J Cell Mol Med 23(1):4–20PubMedCrossRef Li X, He Y, Zeng P, Liu Y, Zhang M, Hao C et al (2019) Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China. J Cell Mol Med 23(1):4–20PubMedCrossRef
21.
go back to reference Zhang L (2019) Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine. Drug Deliv 26(1):860–869PubMedPubMedCentralCrossRef Zhang L (2019) Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine. Drug Deliv 26(1):860–869PubMedPubMedCentralCrossRef
22.
go back to reference Chen M, Xiao D, Liu W, Song Y, Zou B, Li L et al (2020) Intake of Ganoderma lucidum polysaccharides reverses the disturbed gut microbiota and metabolism in type 2 diabetic rats. Int J Biol Macromol 155:890–902PubMedCrossRef Chen M, Xiao D, Liu W, Song Y, Zou B, Li L et al (2020) Intake of Ganoderma lucidum polysaccharides reverses the disturbed gut microbiota and metabolism in type 2 diabetic rats. Int J Biol Macromol 155:890–902PubMedCrossRef
23.
go back to reference Song Q, Cheng SW, Li D, Cheng H, Lai YS, Han Q et al (2022) Gut microbiota mediated hypoglycemic effect of Astragalus membranaceus polysaccharides in db/db mice. Front Pharmacol 13:1043527PubMedPubMedCentralCrossRef Song Q, Cheng SW, Li D, Cheng H, Lai YS, Han Q et al (2022) Gut microbiota mediated hypoglycemic effect of Astragalus membranaceus polysaccharides in db/db mice. Front Pharmacol 13:1043527PubMedPubMedCentralCrossRef
24.
go back to reference Zhou W, Yang T, Xu W, Huang Y, Ran L, Yan Y et al (2022)The polysaccharides from the fruits of Lycium barbarum L. confer anti-diabetic effect by regulating gut microbiota and intestinal barrier. Carbohydr Polym 291:119626. Zhou W, Yang T, Xu W, Huang Y, Ran L, Yan Y et al (2022)The polysaccharides from the fruits of Lycium barbarum L. confer anti-diabetic effect by regulating gut microbiota and intestinal barrier. Carbohydr Polym 291:119626.
25.
go back to reference Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C et al (2013) Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 8(8):e71108PubMedPubMedCentralCrossRef Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C et al (2013) Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 8(8):e71108PubMedPubMedCentralCrossRef
26.
go back to reference Salamon D, Sroka-Oleksiak A, Kapusta P, Szopa M, Mrozińska S, Ludwig-Słomczyńska AH et al (2018) Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next-generation sequencing of the 16S rRNA gene fragment. Pol Arch Intern Med 128(6):336–343PubMed Salamon D, Sroka-Oleksiak A, Kapusta P, Szopa M, Mrozińska S, Ludwig-Słomczyńska AH et al (2018) Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next-generation sequencing of the 16S rRNA gene fragment. Pol Arch Intern Med 128(6):336–343PubMed
27.
go back to reference Zhao L, Lou H, Peng Y, Chen S, Zhang Y, Li X (2019) Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications. Endocrine 66(3):526–537PubMedCrossRef Zhao L, Lou H, Peng Y, Chen S, Zhang Y, Li X (2019) Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications. Endocrine 66(3):526–537PubMedCrossRef
28.
go back to reference Wang J, Li W, Wang C, Wang L, He T, Hu H et al (2020) Enterotype bacteroides is associated with a high risk in patients with diabetes: a pilot study. J Diabetes Res 2020:6047145PubMedPubMedCentralCrossRef Wang J, Li W, Wang C, Wang L, He T, Hu H et al (2020) Enterotype bacteroides is associated with a high risk in patients with diabetes: a pilot study. J Diabetes Res 2020:6047145PubMedPubMedCentralCrossRef
29.
go back to reference Hung WC, Hung WW, Tsai HJ, Chang CC, Chiu YW, Hwang SJ et al (2021) The association of targeted gut microbiota with body composition in Type 2 Diabetes mellitus. Int J Med Sci 18(2):511–519PubMedPubMedCentralCrossRef Hung WC, Hung WW, Tsai HJ, Chang CC, Chiu YW, Hwang SJ et al (2021) The association of targeted gut microbiota with body composition in Type 2 Diabetes mellitus. Int J Med Sci 18(2):511–519PubMedPubMedCentralCrossRef
30.
go back to reference Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK et al (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5(2):e9085PubMedPubMedCentralCrossRef Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK et al (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 5(2):e9085PubMedPubMedCentralCrossRef
31.
go back to reference Fassatoui M, Lopez-Siles M, Díaz-Rizzolo DA, Jmel H, Naouali C, Abdessalem G et al (2019) Gut microbiota imbalances in Tunisian participants with type 1 and type 2 diabetes mellitus. Biosci Rep 39(6). Fassatoui M, Lopez-Siles M, Díaz-Rizzolo DA, Jmel H, Naouali C, Abdessalem G et al (2019) Gut microbiota imbalances in Tunisian participants with type 1 and type 2 diabetes mellitus. Biosci Rep 39(6).
32.
go back to reference Xia F, Wen LP, Ge BC, Li YX, Li FP, Zhou BJ (2021) Gut microbiota as a target for prevention and treatment of type 2 diabetes: Mechanisms and dietary natural products. World J Diabetes 12(8):1146–1163PubMedPubMedCentralCrossRef Xia F, Wen LP, Ge BC, Li YX, Li FP, Zhou BJ (2021) Gut microbiota as a target for prevention and treatment of type 2 diabetes: Mechanisms and dietary natural products. World J Diabetes 12(8):1146–1163PubMedPubMedCentralCrossRef
34.
go back to reference Saad MJ, Santos A, Prada PO (2016) Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology (Bethesda) 31(4):283–293PubMed Saad MJ, Santos A, Prada PO (2016) Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology (Bethesda) 31(4):283–293PubMed
35.
go back to reference Ichimura A, Kimura I (2015) Editorial: obesity and diabetes: energy regulation by free fatty acid receptors. Front Endocrinol (Lausanne) 6:178PubMedCrossRef Ichimura A, Kimura I (2015) Editorial: obesity and diabetes: energy regulation by free fatty acid receptors. Front Endocrinol (Lausanne) 6:178PubMedCrossRef
37.
go back to reference Ren T, Liu F, Wang D, Li B, Jiang P, Li J et al (2023) Rhamnogalacturonan-I enriched pectin from steamed ginseng ameliorates lipid metabolism in type 2 diabetic rats via gut microbiota and AMPK pathway. J Ethnopharmacol 301:115862PubMedCrossRef Ren T, Liu F, Wang D, Li B, Jiang P, Li J et al (2023) Rhamnogalacturonan-I enriched pectin from steamed ginseng ameliorates lipid metabolism in type 2 diabetic rats via gut microbiota and AMPK pathway. J Ethnopharmacol 301:115862PubMedCrossRef
38.
go back to reference Liu H, Xing Y, Wang Y, Ren X, Zhang D, Dai J et al (2023) Dendrobium officinale polysaccharide prevents diabetes via the regulation of gut microbiota in prediabetic mice. Foods 12(12). Liu H, Xing Y, Wang Y, Ren X, Zhang D, Dai J et al (2023) Dendrobium officinale polysaccharide prevents diabetes via the regulation of gut microbiota in prediabetic mice. Foods 12(12).
39.
go back to reference Xia T, Liu CS, Hu YN, Luo ZY, Chen FL, Yuan LX et al (2021) Coix seed polysaccharides alleviate type 2 diabetes mellitus via gut microbiota-derived short-chain fatty acids activation of IGF1/PI3K/AKT signaling. Food Res Int 150(Pt A):110717PubMedCrossRef Xia T, Liu CS, Hu YN, Luo ZY, Chen FL, Yuan LX et al (2021) Coix seed polysaccharides alleviate type 2 diabetes mellitus via gut microbiota-derived short-chain fatty acids activation of IGF1/PI3K/AKT signaling. Food Res Int 150(Pt A):110717PubMedCrossRef
40.
go back to reference Chen Y, Song S, Shu A, Liu L, Jiang J, Jiang M et al (2022) The Herb Pair Radix Rehmanniae and Cornus officinalis attenuated testicular damage in mice with diabetes mellitus through butyric acid/glucagon-like peptide-1/glucagon-like peptide-1 receptor pathway mediated by gut microbiota. Front Microbiol 13:831881PubMedPubMedCentralCrossRef Chen Y, Song S, Shu A, Liu L, Jiang J, Jiang M et al (2022) The Herb Pair Radix Rehmanniae and Cornus officinalis attenuated testicular damage in mice with diabetes mellitus through butyric acid/glucagon-like peptide-1/glucagon-like peptide-1 receptor pathway mediated by gut microbiota. Front Microbiol 13:831881PubMedPubMedCentralCrossRef
41.
go back to reference Hou D, Zhao Q, Chen B, Ren X, Yousaf L, Shen Q (2021) Dietary supplementation with mung bean coat alleviates the disorders in serum glucose and lipid profile and modulates gut microbiota in high-fat diet and streptozotocin-induced prediabetic mice. J Food Sci 86(9):4183–4196PubMedCrossRef Hou D, Zhao Q, Chen B, Ren X, Yousaf L, Shen Q (2021) Dietary supplementation with mung bean coat alleviates the disorders in serum glucose and lipid profile and modulates gut microbiota in high-fat diet and streptozotocin-induced prediabetic mice. J Food Sci 86(9):4183–4196PubMedCrossRef
42.
go back to reference Zhang C, Jia J, Zhang P, Zheng W, Guo X, Ai C et al (2022) Fucoidan from Laminaria japonica Ameliorates Type 2 Diabetes Mellitus in association with modulation of gut microbiota and metabolites in streptozocin-treated mice. Foods 12(1). Zhang C, Jia J, Zhang P, Zheng W, Guo X, Ai C et al (2022) Fucoidan from Laminaria japonica Ameliorates Type 2 Diabetes Mellitus in association with modulation of gut microbiota and metabolites in streptozocin-treated mice. Foods 12(1).
43.
go back to reference Zhang Y, Peng Y, Zhao L, Zhou G, Li X (2021) Regulating the gut microbiota and SCFAs in the faeces of T2DM rats should be one of antidiabetic mechanisms of mogrosides in the fruits of Siraitia grosvenorii. J Ethnopharmacol 274:114033PubMedCrossRef Zhang Y, Peng Y, Zhao L, Zhou G, Li X (2021) Regulating the gut microbiota and SCFAs in the faeces of T2DM rats should be one of antidiabetic mechanisms of mogrosides in the fruits of Siraitia grosvenorii. J Ethnopharmacol 274:114033PubMedCrossRef
44.
go back to reference Wang D, Wang JX, Yan C, Liu Y, Liu H, Li D et al (2022) Gastrodia elata Blume extract improves high-fat diet-induced type 2 diabetes by regulating gut microbiota and bile acid profile. Front Microbiol 13:1091712PubMedPubMedCentralCrossRef Wang D, Wang JX, Yan C, Liu Y, Liu H, Li D et al (2022) Gastrodia elata Blume extract improves high-fat diet-induced type 2 diabetes by regulating gut microbiota and bile acid profile. Front Microbiol 13:1091712PubMedPubMedCentralCrossRef
45.
go back to reference Zheng XX, Li DX, Li YT, Chen YL, Zhao YL, Ji S et al (2023) Mulberry leaf water extract alleviates type 2 diabetes in mice via modulating gut microbiota-host co-metabolism of branched-chain amino acid. Phytother Res 37(8):3195–3210PubMedCrossRef Zheng XX, Li DX, Li YT, Chen YL, Zhao YL, Ji S et al (2023) Mulberry leaf water extract alleviates type 2 diabetes in mice via modulating gut microbiota-host co-metabolism of branched-chain amino acid. Phytother Res 37(8):3195–3210PubMedCrossRef
46.
go back to reference He QL, Wang HC, Ma YK, Yang RL, Dai ZF, Yang JN et al (2023) Changes in the microbiota and their roles in patients with Type 2 diabetes mellitus. Curr Microbiol 80(4):132PubMedCrossRef He QL, Wang HC, Ma YK, Yang RL, Dai ZF, Yang JN et al (2023) Changes in the microbiota and their roles in patients with Type 2 diabetes mellitus. Curr Microbiol 80(4):132PubMedCrossRef
47.
go back to reference Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X et al (2018) Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 359(6380):1151–1156PubMedCrossRef Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X et al (2018) Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 359(6380):1151–1156PubMedCrossRef
48.
go back to reference Tang R, Li L (2021) Modulation of short-chain fatty acids as potential therapy method for type 2 diabetes mellitus. Can J Infect Dis Med Microbiol 2021:6632266PubMedPubMedCentral Tang R, Li L (2021) Modulation of short-chain fatty acids as potential therapy method for type 2 diabetes mellitus. Can J Infect Dis Med Microbiol 2021:6632266PubMedPubMedCentral
49.
go back to reference Liu P, Wang Y, Yang G, Zhang Q, Meng L, Xin Y et al (2021) The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. Pharmacol Res 165:105420PubMedCrossRef Liu P, Wang Y, Yang G, Zhang Q, Meng L, Xin Y et al (2021) The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesis. Pharmacol Res 165:105420PubMedCrossRef
50.
go back to reference Morrison DJ, Preston T (2016) Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7(3):189–200PubMedPubMedCentralCrossRef Morrison DJ, Preston T (2016) Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7(3):189–200PubMedPubMedCentralCrossRef
51.
go back to reference Sankanagoudar S, Shukla R, Shukla KK, Sharma P (2022) Positive association of branched-chain amino acids with triglyceride and glycated haemoglobin in Indian patients with type 2 diabetes mellitus. Diabetes Metab Syndr 16(4):102481PubMedCrossRef Sankanagoudar S, Shukla R, Shukla KK, Sharma P (2022) Positive association of branched-chain amino acids with triglyceride and glycated haemoglobin in Indian patients with type 2 diabetes mellitus. Diabetes Metab Syndr 16(4):102481PubMedCrossRef
52.
go back to reference Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N et al (2011) Cohort profile: the study of health in Pomerania. Int J Epidemiol 40(2):294–307PubMedCrossRef Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N et al (2011) Cohort profile: the study of health in Pomerania. Int J Epidemiol 40(2):294–307PubMedCrossRef
53.
54.
go back to reference Ni Y, Lohinai Z, Heshiki Y, Dome B, Moldvay J, Dulka E et al (2021) Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients. Isme J 15(11):3207–3220PubMedPubMedCentralCrossRef Ni Y, Lohinai Z, Heshiki Y, Dome B, Moldvay J, Dulka E et al (2021) Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients. Isme J 15(11):3207–3220PubMedPubMedCentralCrossRef
55.
go back to reference Gao R, Meng X, Xue Y, Mao M, Liu Y, Tian X et al (2022) Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus. Front Pharmacol 13:1027212PubMedPubMedCentralCrossRef Gao R, Meng X, Xue Y, Mao M, Liu Y, Tian X et al (2022) Bile acids-gut microbiota crosstalk contributes to the improvement of type 2 diabetes mellitus. Front Pharmacol 13:1027212PubMedPubMedCentralCrossRef
56.
go back to reference Mantovani A, Dalbeni A, Peserico D, Cattazzo F, Bevilacqua M, Salvagno GL et al (2021) Plasma bile acid profile in patients with and without type 2 diabetes. Metabolites 11(7). Mantovani A, Dalbeni A, Peserico D, Cattazzo F, Bevilacqua M, Salvagno GL et al (2021) Plasma bile acid profile in patients with and without type 2 diabetes. Metabolites 11(7).
57.
go back to reference Majait S, Nieuwdorp M, Kemper M, Soeters M (2023) The black box orchestra of gut bacteria and bile acids: who is the conductor? Int J Mol Sci 24(3). Majait S, Nieuwdorp M, Kemper M, Soeters M (2023) The black box orchestra of gut bacteria and bile acids: who is the conductor? Int J Mol Sci 24(3).
58.
go back to reference Archundia Herrera MC, Subhan FB, Chan CB (2017) Dietary patterns and cardiovascular disease risk in people with type 2 diabetes. Curr Obes Rep 6(4):405–413PubMedCrossRef Archundia Herrera MC, Subhan FB, Chan CB (2017) Dietary patterns and cardiovascular disease risk in people with type 2 diabetes. Curr Obes Rep 6(4):405–413PubMedCrossRef
59.
go back to reference Seto SW, Lam TY, Tam HL, Au AL, Chan SW, Wu JH et al (2009) Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine 16(5):426–436PubMedCrossRef Seto SW, Lam TY, Tam HL, Au AL, Chan SW, Wu JH et al (2009) Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine 16(5):426–436PubMedCrossRef
60.
go back to reference Teng BS, Wang CD, Zhang D, Wu JS, Pan D, Pan LF et al (2012) Hypoglycemic effect and mechanism of a proteoglycan from Ganoderma lucidum on streptozotocin-induced type 2 diabetic rats. Eur Rev Med Pharmacol Sci 16(2):166–175PubMed Teng BS, Wang CD, Zhang D, Wu JS, Pan D, Pan LF et al (2012) Hypoglycemic effect and mechanism of a proteoglycan from Ganoderma lucidum on streptozotocin-induced type 2 diabetic rats. Eur Rev Med Pharmacol Sci 16(2):166–175PubMed
61.
go back to reference Liang H, Pan Y, Teng Y, Yuan S, Wu X, Yang H et al (2020) A proteoglycan extract from Ganoderma lucidum protects pancreatic beta-cells against STZ-induced apoptosis. Biosci Biotechnol Biochem 84(12):2491–2498PubMedCrossRef Liang H, Pan Y, Teng Y, Yuan S, Wu X, Yang H et al (2020) A proteoglycan extract from Ganoderma lucidum protects pancreatic beta-cells against STZ-induced apoptosis. Biosci Biotechnol Biochem 84(12):2491–2498PubMedCrossRef
62.
go back to reference Zhang Y, Li X, Ruan J, Wang T, Dong Y, Hao J et al (2016) Oleanane type saponins from the stems of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao. Fitoterapia. 2016;109:99–105. Zhang Y, Li X, Ruan J, Wang T, Dong Y, Hao J et al (2016) Oleanane type saponins from the stems of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao. Fitoterapia. 2016;109:99–105.
63.
go back to reference Mao XQ, Yu F, Wang N, Wu Y, Zou F, Wu K et al (2009) Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism. Phytomedicine 16(5):416–425PubMedCrossRef Mao XQ, Yu F, Wang N, Wu Y, Zou F, Wu K et al (2009) Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism. Phytomedicine 16(5):416–425PubMedCrossRef
64.
go back to reference Zhu Y, Su Y, Zhang J, Zhang Y, Li Y, Han Y et al (2021) Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy. Mol Med Rep 23(6). Zhu Y, Su Y, Zhang J, Zhang Y, Li Y, Han Y et al (2021) Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy. Mol Med Rep 23(6).
65.
go back to reference Chen X, Chen C, Fu X (2022) Hypoglycemic effect of the polysaccharides from Astragalus membranaceus on type 2 diabetic mice based on the “gut microbiota-mucosal barrier.” Food Funct 13(19):10121–10133PubMedCrossRef Chen X, Chen C, Fu X (2022) Hypoglycemic effect of the polysaccharides from Astragalus membranaceus on type 2 diabetic mice based on the “gut microbiota-mucosal barrier.” Food Funct 13(19):10121–10133PubMedCrossRef
66.
go back to reference Chen X, Chen C, Fu X (2022) Hypoglycemic activity in vitro and vivo of a water-soluble polysaccharide from Astragalus membranaceus. Food Funct 13(21):11210–11222PubMedCrossRef Chen X, Chen C, Fu X (2022) Hypoglycemic activity in vitro and vivo of a water-soluble polysaccharide from Astragalus membranaceus. Food Funct 13(21):11210–11222PubMedCrossRef
67.
go back to reference Wang WK, Fan L, Ge F, Li Z, Zhu J, Yin K et al (2022) Effects of Danggui Buxue decoction on host gut microbiota and metabolism in GK rats with type 2 diabetes. Front Microbiol 13:1029409PubMedPubMedCentralCrossRef Wang WK, Fan L, Ge F, Li Z, Zhu J, Yin K et al (2022) Effects of Danggui Buxue decoction on host gut microbiota and metabolism in GK rats with type 2 diabetes. Front Microbiol 13:1029409PubMedPubMedCentralCrossRef
69.
go back to reference Retraction: Polysaccharide IV from Lycium barbarum L. improves lipid profiles of gestational diabetes mellitus of pregnancy by upregulating ABCA1 and downregulating sterol regulatory element-binding transcription 1 via miR-33. Front Endocrinol (Lausanne). 13:1130062 (2022). Retraction: Polysaccharide IV from Lycium barbarum L. improves lipid profiles of gestational diabetes mellitus of pregnancy by upregulating ABCA1 and downregulating sterol regulatory element-binding transcription 1 via miR-33. Front Endocrinol (Lausanne). 13:1130062 (2022).
70.
go back to reference Yang S, Li F, Lu S, Ren L, Bian S, Liu M et al (2022) Ginseng root extract attenuates inflammation by inhibiting the MAPK/NF-κB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. J Ethnopharmacol 283:114739PubMedCrossRef Yang S, Li F, Lu S, Ren L, Bian S, Liu M et al (2022) Ginseng root extract attenuates inflammation by inhibiting the MAPK/NF-κB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. J Ethnopharmacol 283:114739PubMedCrossRef
71.
go back to reference Jiang L, Fu Q, Wang S, Chen Y, Li J, Xiao Y et al (2022) Effect of RG (Coptis root and ginseng) formula in patients with type 2 diabetes mellitus: a study protocol for a randomized controlled and double-blinding trial. Trials 23(1):305PubMedPubMedCentralCrossRef Jiang L, Fu Q, Wang S, Chen Y, Li J, Xiao Y et al (2022) Effect of RG (Coptis root and ginseng) formula in patients with type 2 diabetes mellitus: a study protocol for a randomized controlled and double-blinding trial. Trials 23(1):305PubMedPubMedCentralCrossRef
72.
go back to reference Li J, Qiang FU, Shidong W, Jinxi Z, Yu C, Jiayue LI et al (2023) Effects of Shenlian formula on microbiota and inflammatory cytokines in adults with type 2 diabetes: a double-blind randomized clinical trial. J Tradit Chin Med 43(4):760–769PubMedPubMedCentral Li J, Qiang FU, Shidong W, Jinxi Z, Yu C, Jiayue LI et al (2023) Effects of Shenlian formula on microbiota and inflammatory cytokines in adults with type 2 diabetes: a double-blind randomized clinical trial. J Tradit Chin Med 43(4):760–769PubMedPubMedCentral
73.
go back to reference Wang Y, Tong Y, Adejobi OI, Wang Y, Liu A (2021) Research advances in multi-omics on the traditional Chinese herb Dendrobium officinale. Front Plant Sci 12:808228PubMedCrossRef Wang Y, Tong Y, Adejobi OI, Wang Y, Liu A (2021) Research advances in multi-omics on the traditional Chinese herb Dendrobium officinale. Front Plant Sci 12:808228PubMedCrossRef
74.
go back to reference Peng D, Tian W, An M, Chen Y, Zeng W, Zhu S et al (2023) Characterization of antidiabetic effects of Dendrobium officinale derivatives in a mouse model of type 2 diabetes mellitus. Food Chem 399:133974PubMedCrossRef Peng D, Tian W, An M, Chen Y, Zeng W, Zhu S et al (2023) Characterization of antidiabetic effects of Dendrobium officinale derivatives in a mouse model of type 2 diabetes mellitus. Food Chem 399:133974PubMedCrossRef
75.
go back to reference Chen X, Chen C, Fu X (2023) Dendrobium officinale polysaccharide alleviates type 2 diabetes mellitus by restoring gut microbiota and repairing intestinal barrier via the LPS/TLR4/TRIF/NF-kB Axis. J Agric Food Chem 71(31):11929–11940PubMedCrossRef Chen X, Chen C, Fu X (2023) Dendrobium officinale polysaccharide alleviates type 2 diabetes mellitus by restoring gut microbiota and repairing intestinal barrier via the LPS/TLR4/TRIF/NF-kB Axis. J Agric Food Chem 71(31):11929–11940PubMedCrossRef
76.
go back to reference Long XS, Liao ST, Li EN, Pang DR, Li Q, Liu SC et al (2021) The hypoglycemic effect of freeze-dried fermented mulberry mixed with soybean on type 2 diabetes mellitus. Food Sci Nutr 9(7):3641–3654PubMedPubMedCentralCrossRef Long XS, Liao ST, Li EN, Pang DR, Li Q, Liu SC et al (2021) The hypoglycemic effect of freeze-dried fermented mulberry mixed with soybean on type 2 diabetes mellitus. Food Sci Nutr 9(7):3641–3654PubMedPubMedCentralCrossRef
77.
go back to reference Hu B, Yin T, Zhang J, Liu M, Yun H, Wang J et al (2023) Effect of “maccog” TCM tea on improving glucolipid metabolism and gut microbiota in patients with type 2 diabetes in community. Front Endocrinol (Lausanne) 14:1134877PubMedCrossRef Hu B, Yin T, Zhang J, Liu M, Yun H, Wang J et al (2023) Effect of “maccog” TCM tea on improving glucolipid metabolism and gut microbiota in patients with type 2 diabetes in community. Front Endocrinol (Lausanne) 14:1134877PubMedCrossRef
78.
go back to reference Ren X, Xing Y, He L, Xiu Z, Yang L, Han A et al (2022) Effect of 1-Deoxynojirimycin on insulin resistance in prediabetic mice based on next-generation sequencing and intestinal microbiota study. J Ethnopharmacol 289:115029PubMedCrossRef Ren X, Xing Y, He L, Xiu Z, Yang L, Han A et al (2022) Effect of 1-Deoxynojirimycin on insulin resistance in prediabetic mice based on next-generation sequencing and intestinal microbiota study. J Ethnopharmacol 289:115029PubMedCrossRef
79.
go back to reference Zhou Q, Yu R, Liu T, Li Y, Zhong J, Zhang T et al (2021) Coix seed diet ameliorates immune function disorders in experimental colitis mice. Nutrients 14(1). Zhou Q, Yu R, Liu T, Li Y, Zhong J, Zhang T et al (2021) Coix seed diet ameliorates immune function disorders in experimental colitis mice. Nutrients 14(1).
80.
go back to reference Liu S, Li F, Zhang X (2019) Structural modulation of gut microbiota reveals Coix seed contributes to weight loss in mice. Appl Microbiol Biotechnol 103(13):5311–5321PubMedCrossRef Liu S, Li F, Zhang X (2019) Structural modulation of gut microbiota reveals Coix seed contributes to weight loss in mice. Appl Microbiol Biotechnol 103(13):5311–5321PubMedCrossRef
81.
go back to reference Ferretti R, Moura EG, Dos Santos VC, Caldeira EJ, Conte M, Matsumura CY et al (2018) High-fat diet suppresses the positive effect of creatine supplementation on skeletal muscle function by reducing protein expression of IGF-PI3K-AKT-mTOR pathway. PLoS ONE 13(10):e0199728PubMedPubMedCentralCrossRef Ferretti R, Moura EG, Dos Santos VC, Caldeira EJ, Conte M, Matsumura CY et al (2018) High-fat diet suppresses the positive effect of creatine supplementation on skeletal muscle function by reducing protein expression of IGF-PI3K-AKT-mTOR pathway. PLoS ONE 13(10):e0199728PubMedPubMedCentralCrossRef
82.
go back to reference Zhan HD, Zhou HY, Sui YP, Du XL, Wang WH, Dai L et al (2016) The rhizome of Gastrodia elata Blume—an ethnopharmacological review. J Ethnopharmacol 189:361–385PubMedCrossRef Zhan HD, Zhou HY, Sui YP, Du XL, Wang WH, Dai L et al (2016) The rhizome of Gastrodia elata Blume—an ethnopharmacological review. J Ethnopharmacol 189:361–385PubMedCrossRef
83.
go back to reference Bai Y, Mo K, Wang G, Chen W, Zhang W, Guo Y et al (2021) Intervention of Gastrodin in type 2 diabetes mellitus and its mechanism. Front Pharmacol 12:710722PubMedPubMedCentralCrossRef Bai Y, Mo K, Wang G, Chen W, Zhang W, Guo Y et al (2021) Intervention of Gastrodin in type 2 diabetes mellitus and its mechanism. Front Pharmacol 12:710722PubMedPubMedCentralCrossRef
84.
go back to reference Yang HJ, Kim MJ, Kwon DY, Kim DS, Lee YH, Kim JE et al (2016) Anti-diabetic activities of Gastrodia elata blume water extracts are mediated mainly by potentiating glucose-stimulated insulin secretion and increasing β-cell mass in non-obese type 2 diabetic animals. Nutrients 8(3):161PubMedPubMedCentralCrossRef Yang HJ, Kim MJ, Kwon DY, Kim DS, Lee YH, Kim JE et al (2016) Anti-diabetic activities of Gastrodia elata blume water extracts are mediated mainly by potentiating glucose-stimulated insulin secretion and increasing β-cell mass in non-obese type 2 diabetic animals. Nutrients 8(3):161PubMedPubMedCentralCrossRef
85.
go back to reference Ye T, Meng X, Zhai Y, Xie W, Wang R, Sun G et al (2018) Gastrodin ameliorates cognitive dysfunction in diabetes rat model via the suppression of endoplasmic reticulum stress and NLRP3 inflammasome activation. Front Pharmacol 9:1346PubMedPubMedCentralCrossRef Ye T, Meng X, Zhai Y, Xie W, Wang R, Sun G et al (2018) Gastrodin ameliorates cognitive dysfunction in diabetes rat model via the suppression of endoplasmic reticulum stress and NLRP3 inflammasome activation. Front Pharmacol 9:1346PubMedPubMedCentralCrossRef
86.
87.
go back to reference Peng ZC, He J, Pan XG, Zhang J, Wang YM, Ye XS et al (2021) Secoiridoid dimers and their biogenetic precursors from the fruits of Cornus officinalis with potential therapeutic effects on type 2 diabetes. Bioorg Chem 117:105399PubMedCrossRef Peng ZC, He J, Pan XG, Zhang J, Wang YM, Ye XS et al (2021) Secoiridoid dimers and their biogenetic precursors from the fruits of Cornus officinalis with potential therapeutic effects on type 2 diabetes. Bioorg Chem 117:105399PubMedCrossRef
88.
go back to reference Hou D, Yousaf L, Xue Y, Hu J, Wu J, Hu X et al (2019) Mung bean (Vigna radiata L.): bioactive polyphenols, polysaccharides, peptides, and health benefits. Nutrients 11(6). Hou D, Yousaf L, Xue Y, Hu J, Wu J, Hu X et al (2019) Mung bean (Vigna radiata L.): bioactive polyphenols, polysaccharides, peptides, and health benefits. Nutrients 11(6).
89.
go back to reference Mayachiew P, Charunuch C, Devahastin S (2015) Physicochemical and thermal properties of extruded instant functional rice porridge powder as affected by the addition of soybean or mung bean. J Food Sci 80(12):E2782–E2791PubMedCrossRef Mayachiew P, Charunuch C, Devahastin S (2015) Physicochemical and thermal properties of extruded instant functional rice porridge powder as affected by the addition of soybean or mung bean. J Food Sci 80(12):E2782–E2791PubMedCrossRef
90.
go back to reference Saeting O, Chandarajoti K, Phongphisutthinan A, Hongsprabhas P, Sae-Tan S (2021) Water extract of mungbean (Vigna radiata L.) inhibits protein tyrosine phosphatase-1B in insulin-resistant HepG2 cells. Molecules 26(5). Saeting O, Chandarajoti K, Phongphisutthinan A, Hongsprabhas P, Sae-Tan S (2021) Water extract of mungbean (Vigna radiata L.) inhibits protein tyrosine phosphatase-1B in insulin-resistant HepG2 cells. Molecules 26(5).
91.
go back to reference Charoensiddhi S, Chanput WP, Sae-Tan S (2022) Gut microbiota modulation, anti-diabetic and anti-inflammatory properties of polyphenol extract from mung bean seed coat (Vigna radiata L.). Nutrients 14(11). Charoensiddhi S, Chanput WP, Sae-Tan S (2022) Gut microbiota modulation, anti-diabetic and anti-inflammatory properties of polyphenol extract from mung bean seed coat (Vigna radiata L.). Nutrients 14(11).
92.
go back to reference Li HY, Yi YL, Guo S, Zhang F, Yan H, Zhan ZL et al (2022) Isolation, structural characterization and bioactivities of polysaccharides from Laminaria japonica: a review. Food Chem 370:131010PubMedCrossRef Li HY, Yi YL, Guo S, Zhang F, Yan H, Zhan ZL et al (2022) Isolation, structural characterization and bioactivities of polysaccharides from Laminaria japonica: a review. Food Chem 370:131010PubMedCrossRef
93.
go back to reference Wang X, Zhang L, Qin L, Wang Y, Chen F, Qu C et al (2022) Physicochemical properties of the soluble dietary fiber from Laminaria japonica and its role in the regulation of Type 2 diabetes mice. Nutrients 14(2). Wang X, Zhang L, Qin L, Wang Y, Chen F, Qu C et al (2022) Physicochemical properties of the soluble dietary fiber from Laminaria japonica and its role in the regulation of Type 2 diabetes mice. Nutrients 14(2).
94.
go back to reference Wu N, Jin W, Zhao Y, Wang H, He S, Zhang W et al (2022) Sulfated Fucogalactan from Laminaria japonica Ameliorates β-cell failure by attenuating mitochondrial dysfunction via SIRT1-PGC1-α signaling pathway activation. Front Endocrinol (Lausanne) 13:881256PubMedCrossRef Wu N, Jin W, Zhao Y, Wang H, He S, Zhang W et al (2022) Sulfated Fucogalactan from Laminaria japonica Ameliorates β-cell failure by attenuating mitochondrial dysfunction via SIRT1-PGC1-α signaling pathway activation. Front Endocrinol (Lausanne) 13:881256PubMedCrossRef
95.
go back to reference Gong X, Chen N, Ren K, Jia J, Wei K, Zhang L et al (2019) The fruits of Siraitia grosvenorii: a review of a Chinese food-medicine. Front Pharmacol 10:1400PubMedPubMedCentralCrossRef Gong X, Chen N, Ren K, Jia J, Wei K, Zhang L et al (2019) The fruits of Siraitia grosvenorii: a review of a Chinese food-medicine. Front Pharmacol 10:1400PubMedPubMedCentralCrossRef
96.
go back to reference Li C, Lin LM, Sui F, Wang ZM, Huo HR, Dai L et al (2014) Chemistry and pharmacology of Siraitia grosvenorii: a review. Chin J Nat Med 12(2):89–102PubMed Li C, Lin LM, Sui F, Wang ZM, Huo HR, Dai L et al (2014) Chemistry and pharmacology of Siraitia grosvenorii: a review. Chin J Nat Med 12(2):89–102PubMed
97.
go back to reference Zhou G, Zhang Y, Li Y, Wang M, Li X (2018) The metabolism of a natural product mogroside V, in healthy and type 2 diabetic rats. J Chromatogr B Analyt Technol Biomed Life Sci 1079:25–33PubMedCrossRef Zhou G, Zhang Y, Li Y, Wang M, Li X (2018) The metabolism of a natural product mogroside V, in healthy and type 2 diabetic rats. J Chromatogr B Analyt Technol Biomed Life Sci 1079:25–33PubMedCrossRef
98.
go back to reference Liu H, Qi X, Yu K, Lu A, Lin K, Zhu J et al (2019) AMPK activation is involved in hypoglycemic and hypolipidemic activities of mogroside-rich extract from Siraitia grosvenorii (Swingle) fruits on high-fat diet/streptozotocin-induced diabetic mice. Food Funct 10(1):151–162PubMedCrossRef Liu H, Qi X, Yu K, Lu A, Lin K, Zhu J et al (2019) AMPK activation is involved in hypoglycemic and hypolipidemic activities of mogroside-rich extract from Siraitia grosvenorii (Swingle) fruits on high-fat diet/streptozotocin-induced diabetic mice. Food Funct 10(1):151–162PubMedCrossRef
101.
go back to reference Malko P, Jia X, Wood I, Jiang LH (2023) Piezo1 channel-mediated Ca(2+) signaling inhibits lipopolysaccharide-induced activation of the NF-κB inflammatory signaling pathway and generation of TNF-α and IL-6 in microglial cells. Glia 71(4):848–865PubMedCrossRef Malko P, Jia X, Wood I, Jiang LH (2023) Piezo1 channel-mediated Ca(2+) signaling inhibits lipopolysaccharide-induced activation of the NF-κB inflammatory signaling pathway and generation of TNF-α and IL-6 in microglial cells. Glia 71(4):848–865PubMedCrossRef
102.
go back to reference Tedelind S, Westberg F, Kjerrulf M, Vidal A (2007) Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 13(20):2826–2832PubMedPubMedCentralCrossRef Tedelind S, Westberg F, Kjerrulf M, Vidal A (2007) Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 13(20):2826–2832PubMedPubMedCentralCrossRef
103.
go back to reference Ulven T (2012) Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) 3:111PubMedCrossRef Ulven T (2012) Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) 3:111PubMedCrossRef
104.
go back to reference Bindels LB, Dewulf EM, Delzenne NM (2013) GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 34(4):226–232PubMedCrossRef Bindels LB, Dewulf EM, Delzenne NM (2013) GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 34(4):226–232PubMedCrossRef
105.
go back to reference Lee SU, In HJ, Kwon MS, Park BO, Jo M, Kim MO et al (2013) β-Arrestin 2 mediates G protein-coupled receptor 43 signals to nuclear factor-κB. Biol Pharm Bull 36(11):1754–1759PubMedCrossRef Lee SU, In HJ, Kwon MS, Park BO, Jo M, Kim MO et al (2013) β-Arrestin 2 mediates G protein-coupled receptor 43 signals to nuclear factor-κB. Biol Pharm Bull 36(11):1754–1759PubMedCrossRef
106.
go back to reference Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B et al (2004) Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol Cell 14(3):303–317PubMedCrossRef Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B et al (2004) Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol Cell 14(3):303–317PubMedCrossRef
107.
go back to reference Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS et al (2020) Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 27(4):659–70.e5PubMedPubMedCentralCrossRef Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS et al (2020) Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 27(4):659–70.e5PubMedPubMedCentralCrossRef
108.
go back to reference Hu J, Wang C, Huang X, Yi S, Pan S, Zhang Y et al (2021) Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling. Cell Rep 36(12):109726PubMedCrossRef Hu J, Wang C, Huang X, Yi S, Pan S, Zhang Y et al (2021) Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling. Cell Rep 36(12):109726PubMedCrossRef
109.
go back to reference Xiao H, Sun X, Liu R, Chen Z, Lin Z, Yang Y et al (2020) Gentiopicroside activates the bile acid receptor Gpbar1 (TGR5) to repress NF-kappaB pathway and ameliorate diabetic nephropathy. Pharmacol Res 151:104559PubMedCrossRef Xiao H, Sun X, Liu R, Chen Z, Lin Z, Yang Y et al (2020) Gentiopicroside activates the bile acid receptor Gpbar1 (TGR5) to repress NF-kappaB pathway and ameliorate diabetic nephropathy. Pharmacol Res 151:104559PubMedCrossRef
110.
go back to reference Liu H, Wang J, Ding Y, Shi X, Ren H (2022) Antibiotic pretreatment attenuates liver ischemia-reperfusion injury by Farnesoid X receptor activation. Cell Death Dis 13(5):484PubMedPubMedCentralCrossRef Liu H, Wang J, Ding Y, Shi X, Ren H (2022) Antibiotic pretreatment attenuates liver ischemia-reperfusion injury by Farnesoid X receptor activation. Cell Death Dis 13(5):484PubMedPubMedCentralCrossRef
111.
go back to reference Yu JH, Zheng JB, Qi J, Yang K, Wu YH, Wang K et al (2019) Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway. Int J Oncol 54(3):879–892PubMedPubMedCentral Yu JH, Zheng JB, Qi J, Yang K, Wu YH, Wang K et al (2019) Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway. Int J Oncol 54(3):879–892PubMedPubMedCentral
112.
go back to reference Dalile B, Van Oudenhove L, Vervliet B, Verbeke K (2019) The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol 16(8):461–478PubMedCrossRef Dalile B, Van Oudenhove L, Vervliet B, Verbeke K (2019) The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol 16(8):461–478PubMedCrossRef
113.
go back to reference Jorsal T, Rhee NA, Pedersen J, Wahlgren CD, Mortensen B, Jepsen SL et al (2018) Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia 61(2):284–294PubMedCrossRef Jorsal T, Rhee NA, Pedersen J, Wahlgren CD, Mortensen B, Jepsen SL et al (2018) Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia 61(2):284–294PubMedCrossRef
114.
go back to reference Christiansen CB, Gabe MBN, Svendsen B, Dragsted LO, Rosenkilde MM, Holst JJ (2018) The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. Am J Physiol Gastrointest Liver Physiol 315(1):G53-g65PubMedCrossRef Christiansen CB, Gabe MBN, Svendsen B, Dragsted LO, Rosenkilde MM, Holst JJ (2018) The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. Am J Physiol Gastrointest Liver Physiol 315(1):G53-g65PubMedCrossRef
115.
go back to reference Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J et al (2021) Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab 33(4):791-803.e7PubMedCrossRef Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J et al (2021) Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab 33(4):791-803.e7PubMedCrossRef
116.
go back to reference Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740–756PubMedCrossRef Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740–756PubMedCrossRef
117.
go back to reference Maneschi E, Vignozzi L, Morelli A, Mello T, Filippi S, Cellai I et al (2013) FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J Endocrinol 218(2):215–231PubMedCrossRef Maneschi E, Vignozzi L, Morelli A, Mello T, Filippi S, Cellai I et al (2013) FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J Endocrinol 218(2):215–231PubMedCrossRef
118.
go back to reference Dimou A, Tsimihodimos V, Bairaktari E (2022) The critical role of the branched chain amino acids (BCAAs) catabolism-regulating enzymes, branched-chain aminotransferase (BCAT) and branched-chain α-keto acid dehydrogenase (BCKD), in human pathophysiology. Int J Mol Sci 23(7). Dimou A, Tsimihodimos V, Bairaktari E (2022) The critical role of the branched chain amino acids (BCAAs) catabolism-regulating enzymes, branched-chain aminotransferase (BCAT) and branched-chain α-keto acid dehydrogenase (BCKD), in human pathophysiology. Int J Mol Sci 23(7).
120.
go back to reference Chen J, Ou Y, Luo R, Wang J, Wang D, Guan J et al (2021) SAR1B senses leucine levels to regulate mTORC1 signalling. Nature 596(7871):281–284PubMedCrossRef Chen J, Ou Y, Luo R, Wang J, Wang D, Guan J et al (2021) SAR1B senses leucine levels to regulate mTORC1 signalling. Nature 596(7871):281–284PubMedCrossRef
121.
go back to reference Marafie SK, Al-Shawaf EM, Abubaker J, Arefanian H (2019) Palmitic acid-induced lipotoxicity promotes a novel interplay between Akt-mTOR, IRS-1, and FFAR1 signaling in pancreatic β-cells. Biol Res 52(1):44PubMedPubMedCentralCrossRef Marafie SK, Al-Shawaf EM, Abubaker J, Arefanian H (2019) Palmitic acid-induced lipotoxicity promotes a novel interplay between Akt-mTOR, IRS-1, and FFAR1 signaling in pancreatic β-cells. Biol Res 52(1):44PubMedPubMedCentralCrossRef
122.
go back to reference Rivera ME, Rivera CN, Vaughan RA (2022) Excess branched-chain amino acids alter myotube metabolism and substrate preference which is worsened by concurrent insulin resistance. Endocrine 76(1):18–28PubMedCrossRef Rivera ME, Rivera CN, Vaughan RA (2022) Excess branched-chain amino acids alter myotube metabolism and substrate preference which is worsened by concurrent insulin resistance. Endocrine 76(1):18–28PubMedCrossRef
123.
go back to reference Jing T, Zhang S, Bai M, Chen Z, Gao S, Li S et al (2021) Effect of dietary approaches on glycemic control in patients with Type 2 diabetes: a systematic review with network meta-analysis of randomized trials. Nutrients 15(14). Jing T, Zhang S, Bai M, Chen Z, Gao S, Li S et al (2021) Effect of dietary approaches on glycemic control in patients with Type 2 diabetes: a systematic review with network meta-analysis of randomized trials. Nutrients 15(14).
124.
go back to reference Liu Y, Wang J, Wu C (2021) Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. Front Nutr 8:634897PubMedCrossRef Liu Y, Wang J, Wu C (2021) Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. Front Nutr 8:634897PubMedCrossRef
125.
go back to reference Salgaço MK, Oliveira LGS, Costa GN, Bianchi F, Sivieri K (2019) Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. Appl Microbiol Biotechnol 103(23–24):9229–9238PubMedCrossRef Salgaço MK, Oliveira LGS, Costa GN, Bianchi F, Sivieri K (2019) Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus. Appl Microbiol Biotechnol 103(23–24):9229–9238PubMedCrossRef
127.
go back to reference Petersen A, Julienne H, Hyötyläinen T, Sen P, Fan Y, Pedersen HK et al (2021) Conjugated C-6 hydroxylated bile acids in serum relate to human metabolic health and gut Clostridia species. Sci Rep 11(1):13252PubMedPubMedCentralCrossRef Petersen A, Julienne H, Hyötyläinen T, Sen P, Fan Y, Pedersen HK et al (2021) Conjugated C-6 hydroxylated bile acids in serum relate to human metabolic health and gut Clostridia species. Sci Rep 11(1):13252PubMedPubMedCentralCrossRef
128.
go back to reference Wang Z, Du H, Peng W, Yang S, Feng Y, Ouyang H et al (2022) Efficacy and mechanism of Pueraria lobata and Pueraria thomsonii polysaccharides in the treatment of type 2 diabetes. Nutrients 14(19). Wang Z, Du H, Peng W, Yang S, Feng Y, Ouyang H et al (2022) Efficacy and mechanism of Pueraria lobata and Pueraria thomsonii polysaccharides in the treatment of type 2 diabetes. Nutrients 14(19).
129.
go back to reference Xu F, Yang J, Negishi H, Sun Y, Li D, Zhang X et al (2018) Silibinin decreases hepatic glucose production through the activation of gut-brain-liver axis in diabetic rats. Food Funct 9(9):4926–4935PubMedCrossRef Xu F, Yang J, Negishi H, Sun Y, Li D, Zhang X et al (2018) Silibinin decreases hepatic glucose production through the activation of gut-brain-liver axis in diabetic rats. Food Funct 9(9):4926–4935PubMedCrossRef
Metadata
Title
Edible traditional Chinese medicines improve type 2 diabetes by modulating gut microbiotal metabolites
Authors
Shen Chen
Yiqiao Jiao
Yiyang Han
Jie Zhang
Yuanyuan Deng
Zilu Yu
Jiao Wang
Shasha He
Wei Cai
Jixiong Xu
Publication date
16-01-2024
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2024
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-023-02217-6

Other articles of this Issue 4/2024

Acta Diabetologica 4/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare